No influence of the MDR-I C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin a trough concentrations or rejection incidence in stable renal transplant recipients

Clinical Chemistry

Volumn 47, Issue 6 I, 2001, Pages 1048-1052

  Von Ahsen, N ^a   Richter, M ^a   Grupp, C ^a   Ringe, B ^a   Oellerich, M ^a   Armstrong, V W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; PREDNISOLONE; CYCLOSPORIN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MIXED FUNCTION OXIDASE;

ARTICLE; CAUCASIAN; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROMOTER REGION; GENETICS; KIDNEY FUNCTION TEST; METABOLISM; PHYSIOLOGY; TRANSPLANTATION;

CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSPLANTATION;

EID: 0034744113     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.6.1048     Document Type: Article

References (19)

1. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus
2. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
3. In vitro and in vivo drug interactions involving human CYP3A
4. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
5. Human P-glycoprotein transports cyclosporin A and FK506
6. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
7. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
8. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
9. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
10. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
11. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
12. Association of CYP3A4 genotype with treatment-related leukemia
13. 1-antitrypsin genotyping by multiplex real-time fluorescence PCR with the LightCycler
14. Molecular and physical mechanisms of first-pass extraction
15. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor
16. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
17. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region
18. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
19. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance